List of Excipients in Branded Drug CEFAZOLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	ANHYDROUS DEXTROSE
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	HYDROCHLORIC ACID
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	SODIUM BICARBONATE
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	SODIUM HYDROXIDE
Baxter Healthcare Corporation	CEFAZOLIN	cefazolin sodium	0338-3508	WATER

Generic Drugs Containing CEFAZOLIN

Company	Ingredient	NDC	Excipient
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	HYDROCHLORIC ACID
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	SODIUM BICARBONATE
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	SODIUM HYDROXIDE
Baxter Healthcare Corporation	cefazolin sodium	0338-3503	WATER

What are the Most Frequently-Used Excipients in CEFAZOLIN?

# Of NDCs	Excipient
1	DEXTROSE MONOHYDRATE
1	HYDROCHLORIC ACID
1	SODIUM BICARBONATE
1	SODIUM HYDROXIDE
1	WATER

Excipient Strategy and Commercial Opportunities for Cefazolin

Last updated: March 2, 2026

What is the role of excipient strategy in cefazolin manufacturing?

Excipient selection for cefazolin influences stability, solubility, bioavailability, and shelf-life. The strategy involves choosing compatible excipients that do not compromise the drug’s efficacy and safety. This impacts formulation performance, manufacturing process simplicity, and regulatory compliance.

What are common excipients used in cefazolin formulations?

Cefazolin is typically formulated as lyophilized powders for reconstitution. Core excipients include:

• Buffers: Sodium acetate or phosphate buffers maintain pH around 5.0–6.0, stabilizing cefazolin.
• Cryoprotectants: Mannitol or sucrose support lyophilization, preserving drug stability.
• Fillers and stabilizers: Sodium chloride for isotonicity and stability.
• Preservatives: Limited use due to potential allergic reactions; not common in all formulations.

Additional excipients like antioxidants are rarely used, given cefazolin’s stability profile.

How does excipient choice impact commercial manufacturing?

Selecting excipients impacts scale-up feasibility, manufacturing costs, and regulatory approvals:

• Stability: Optimized excipients extend shelf life, reduce spoilage, and lower waste.
• Compatibility: Excipients must align with sterilization procedures, such as lyophilization or filtration.
• Regulatory compliance: Use of GRAS (Generally Recognized as Safe) excipients facilitates approval processes.

What are the key considerations in cefazolin excipient development?

• Physicochemical Compatibility: Ensuring excipients do not degrade cefazolin or cause precipitation.
• Physiological Compatibility: Avoiding excipients that may induce allergic reactions when administered.
• Manufacturing Robustness: Simplifying processes like lyophilization and ensuring uniformity.

What are the recent trends in cefazolin excipient innovation?

• Use of novel excipients that enhance stability at room temperature.
• Development of ready-to-use liquid formulations, reducing reconstitution steps.
• Incorporating stabilizing agents that extend shelf life in varied climates.

What commercial opportunities exist in cefazolin excipient markets?

• Differentiation through stability: Formulations with improved shelf life and temperature tolerance meet global needs, especially in emerging markets.
• Generic market expansion: Cost-effective excipient choices reduce production costs, increasing competitiveness.
• Specialized formulations: Lyophilized powders, pre-filled syringes, and ready-to-use solutions broaden application scope.

How does excipient strategy influence regulatory and market access?

Regulatory guidance (e.g., FDA, EMA) emphasizes excipient safety, compatibility, and manufacturing process validation. Transparent documentation and stability data favor faster approval. Custom excipients may require extensive testing, increasing time-to-market.

What are the challenges in optimizing cefazolin excipients?

• Balancing stability with manufacturing costs.
• Ensuring excipient supply chain robustness.
• Meeting diverse global regulatory standards.

Summary Table: Excipient Options and Impacts in Cefazolin Formulation

Excipient Type	Function	Impact on Product	Regulatory Status
Buffer salts	pH stabilization	Preserves cefazolin stability	Generally recognized as safe (GRAS)
Mannitol/Sucrose	Lyophilization support	Improves shelf life, stability	Widely used in parenteral drugs
Sodium chloride	Isotonicity	Enhances compatibility with tissue	Established use
Preservatives	Risk mitigation in multi-dose vials	Less common in single-dose	Strict regulations for preservatives

Key Takeaways

• Excipient choice directly affects cefazolin stability, manufacturability, and regulatory approval.
• Formulation strategies focus on pH control, lyophilization support, and isotonicity.
• Innovation in excipients can extend shelf life, enable temperature stability, and open new markets.
• Cost-effective excipient selection benefits generic manufacturers and global access.
• Regulatory compliance demands thorough compatibility and safety data for excipients.

FAQs

Q1: How do excipients influence cefazolin storage conditions?

Excipient compatibility determines the product's stability at different temperatures and humidity levels. Proper excipients extend shelf life and enable storage without refrigeration.

Q2: Are there any excipients specifically avoided in cefazolin formulations?

Excipients that can degrade cefazolin or cause allergic reactions—such as certain preservatives or incompatible buffers—are avoided unless justified by stability data.

Q3: Can novel excipients improve cefazolin stability at room temperature?

Yes. Some innovative excipients, such as sugars like trehalose or certain polymers, stabilize products at ambient conditions, reducing cold chain dependency.

Q4: How does excipient choice affect global market access?

Use of globally approved, widely accepted excipients streamlines regulatory approval and eases distribution, especially in low- and middle-income countries.

Q5: What regulatory documentation is needed for excipients in cefazolin?

Manufacturers must provide stability data, compatibility assessments, and safety profiles per authorities' guidelines (e.g., FDA's INAD process or EMA’s requirements).

---

References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Stability Testing of Drug Substances and Products.
[2] European Medicines Agency. (2021). Guideline on pharmaceutical stability.
[3] Kwon, Y. J., & Yu, S. (2020). Advanced formulations and stabilizers for cefazolin. Journal of Parenteral and Enteral Nutrition, 44(3), 457–463.